Oncologic safety of breast-conserving surgery in breast cancer patients under the age of 35
- Author:
Incheon KANG
1
;
Joo Heung KIM
;
Seho PARK
;
Ho HUR
;
Hyung Seok PARK
;
Seung Il KIM
;
Young Up CHO
Author Information
- Publication Type:Original Article
- Keywords: Age factors; Breast-conserving surgery; Breast neoplasms; Local neoplasm recurrence; Survival rate
- MeSH: Age Factors; Breast Neoplasms; Breast; Chemotherapy, Adjuvant; Drug Therapy; Follow-Up Studies; Humans; Korea; Mastectomy, Modified Radical; Mastectomy, Segmental; Mastectomy, Simple; Neoplasm Recurrence, Local; Pathology; Recurrence; Survival Rate
- From: Korean Journal of Clinical Oncology 2017;13(1):32-38
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Breast-conserving surgery (BCS) shows no difference in survival rates compared with total mastectomy. So, BCS is considered standard breast surgery with modified radical mastectomy. But in patients who received BCS, there is a risk of local recurrence in their long term follow up periods. Especially, BCS of young age is controversial regarding oncologic safety because of local recurrence. In this study, we struggle to confirm the oncologic safety of BCS compared with total mastectomy under the age of 35 in South Korea.METHODS: All patients who underwent surgery for breast cancer were 5,366 at Severance Hospital, Yonsei University Health System, from January 1981 to April 2008. Of them, patients younger than 35 years old were 547. We excluded patients who received chemotherapy before surgery and included only stage 1 and 2 patients who identified through the pathology after surgery. Finally, we got 367 patients; total mastectomy was performed in 245 and BCS, in 122. We compared clinicopathological characteristics and oncologic outcomes between two groups using SPSS program.RESULTS: In patients received BCS, a local recurrence rate was 7.7% at 5 years and up to 20.3% at 10 years. In patients received total mastectomy, a local recurrence rate was 1.9% over 10 years (P<0.001). However, there was no difference in 5-year and 10-year overall survival rates between two groups (P=0.689). Adjuvant chemotherapy decreased local recurrence rate in BCS patients (P=0.019).CONCLUSION: So, we concluded that BCS under the age of 35 has oncologic safety with undergoing chemotherapy.
